Kim et al. (2023) found that application of the RIP1 inhibitor Necrostatin-1 blocked the necroptosis pathway and pro-inflammatory cytokines TNF-α and IL-1β production, and upregulated the expression of neurotrophic factors and restored dopaminergic neurons in PD mice. This evidence concerns the gene RIPK1 and Parkinson disease.